Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
5-day change
1st Jan Change
5.32
USD
+1.14%
+0.76%
-35.12%
Presentation Operator MessageOperator (Operator)Good day, and thank you for standing by. Welco...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Transcript : OraSure Technologies, Inc., 2023 Earnings Call, Feb 27, 2024
Feb. 27
Earnings Flash (OSUR) ORASURE TECHNOLOGIES Posts Q4 Revenue $75.9M, vs. Street Est of $74.3M
Feb. 27
MT
Earnings Flash (OSUR) ORASURE TECHNOLOGIES Reports Q4 EPS $0.22, vs. Street Est of $0.11
Feb. 27
MT
OraSure Technologies, Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023
Feb. 27
CI
OraSure Technologies, Inc. Provides Revenue Guidance for the First Quarter 2024
Feb. 27
CI
OraSure Technologies, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Feb. 27
CI
OraSure Technologies, Inc. Seeks M&A
Feb. 26
CI
OraSure Technologies Leads Series B Funding, Strikes Distribution Rights With Sapphiros
Jan. 04
MT
Orasure Technologies, Inc. Secures Strategic Distribution Rights with Sapphiros
Jan. 04
CI
Transcript : OraSure Technologies, Inc. - Special Call
Jan. 04
Sapphiros AI Bio LLC announced that it has received $30 million in funding from OraSure Technologies, Inc.
Jan. 03
CI
Citigroup Adjusts OraSure Technologies Price Target to $9 From $7, Maintains Buy Rating
Dec. 11
MT
Tranche Update on OraSure Technologies, Inc.'s Equity Buyback Plan announced on August 5, 2008.
Nov. 08
CI
OraSure Technologies to Seek Acquisitions
Nov. 07
CI
Transcript : OraSure Technologies, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Nov. 07
Earnings Flash (OSUR) ORASURE TECHNOLOGIES Posts Q3 Revenue $89.2M, vs. Street Est of $74.6M
Nov. 07
MT
Earnings Flash (OSUR) ORASURE TECHNOLOGIES Reports Q3 EPS $0.27, vs. Street Est of $0.08
Nov. 07
MT
OraSure Technologies, Inc. Provides Financial Guidance for the Fourth Quarter 2023
Nov. 07
CI
OraSure Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 07
CI
Evercore ISI Adjusts OraSure Technologies Price Target to $6.50 From $5, Maintains In Line Rating
23-08-08
MT
Tranche Update on OraSure Technologies, Inc.'s Equity Buyback Plan announced on August 5, 2008.
23-08-04
CI
Transcript : OraSure Technologies, Inc., Q2 2023 Earnings Call, Aug 03, 2023
23-08-03
Earnings Flash (OSUR) ORASURE TECHNOLOGIES Reports Q2 Revenue $85.4M, vs. Street Est of $63.9M
23-08-03
MT
Earnings Flash (OSUR) ORASURE TECHNOLOGIES Reports Q2 EPS $0.09
23-08-03
MT
OraSure Technologies, Inc. Provides Revenue Guidance for the Third Quarter of 2023
23-08-03
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
OraSure Technologies, Inc. provides point-of-care and home diagnostic tests, sample management solutions, and microbiome laboratory and analytical services. The Company's product portfolio is divided into diagnostics products and sample management solutions. Its business consists of the development, manufacture, marketing and sale of diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Its diagnostic products include tests for diseases including COVID-19, HIV and Hepatitis C that are performed on a rapid basis at the point of care, and tests for drugs of abuse that are processed in a laboratory. Its business also includes molecular sample management solutions and services that are used by clinical laboratories, direct-to-consumer laboratories, researchers, pharmaceutical companies, and animal health service and product providers.
More about the company
Last Close Price
5.32
USD
Average target price
7.55
USD
Spread / Average Target
+41.92%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1